Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo

Cancer Letters

Volumn 268, Issue 1, 2008, Pages 89-97

  Wang, Hongbo ^a   Li, Hongyan ^a   Zuo, Minxin ^a   Zhang, Yi ^a   Liu, He ^a   Fang, Weishuo ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antitumor activity; Cell cycle arrest; Lx2 32c; Microtubule

Indexed keywords

CEPHALOMANNINE; LX 2 32C; LX2 32C; PACLITAXEL; TAXANE DERIVATIVE; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; INCUBATION TIME; LUNG NON SMALL CELL CANCER; MALE; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STOMACH CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRIDGED COMPOUNDS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROTUBULES; PACLITAXEL; STOMACH NEOPLASMS; TAXOIDS; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 48149092967     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.051     Document Type: Article

References (27)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
2. Wyld L., and Reed M. The role of surgery in the management of older women with breast cancer. Eur. J. Cancer 43 (2007) 2253-2263
3. Stenner-Liewen F., Zippelius A., Pestalozzi B.C., and Knuth A. Molecular targeted therapy. Chirurg 77 (2006) 1118-1125
4. Fojo T., and Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann. Oncol. 18 Suppl. 5 (2007) v3-v8
5. Duflos A., Kruczynski A., and Barret J.M. Novel aspects of natural and modified vinca alkaloids. Curr. Med. Chem. Anticancer Agents 2 (2002) 55-70
6. Spencer C.M., and Faulds D. Paclitaxel, A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48 (1994) 794-847
7. Parness J., and Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 91 (1981) 479-487
8. Mekhail T.M., and Markman M. Paclitaxel in cancer therapy. Expert Opin. Pharmacother. 3 (2002) 755-766
9. Wang Y., and Cabral F. Paclitaxel resistance in cells with reduced beta-tubulin. Biochim. Biophys. Acta 1744 (2005) 245-255
10. Schwartsmann G., Ratain M.J., Cragg G.M., Wong J.E., Saijo N., Parkinson D.R., et al. Anticancer drug discovery and development throughout the world. J. Clin. Oncol. 20 (2002) 47S-59S
11. Glowniak K., Zgorka G., Jozefczyk A., and Furmanowa M. Sample preparation for taxol and cephalomannine determination in various organs of Taxus sp. J. Pharm. Biomed. Anal. 14 (1996) 1215-1220
12. Yang C.G., Barasoain I., Li X., Matesanz R., Liu R., Sharom F.J., et al. Overcoming tumor drug resistance with high-affinity taxanes: a SAR study of C2-modified 7-acyl-10-deacetyl cephalomannines. Chem. Med. Chem. 2 (2007) 691-701
13. Jin J., Huang M., Wei H.L., and Liu G.T. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J. Gastroenterol. 8 (2002) 1029-1034
14. Zhang X.H., Zhang F.Y., Ji X.J., and Li Z.Y. Vincristine-resistant human KB cell line and mechanism of multidrug resistance. Yao Xue Xue Bao 29 (1994) 246-251
15. Williams Jr. R.C., and Lee J.C. Preparation of tubulin from brain. Methods Enzymol. 85 (1982) 376-385
16. Bollag D.M., McQueney P.A., Zhu J., Hensens O., Koupal L., Liesch J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55 (1995) 2325-2333
17. Zhao J., Kim J.E., Reed E., and Li Q.Q. Molecular mechanism of antitumor activity of taxanes in lung cancer. Int. J. Oncol. 27 (2005) 247-256 (Review)
18. Abal M., Andreu J.M., and Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets 3 (2003) 193-203
19. Zunino F., Cassinelli G., Polizzi D., and Perego P. Molecular mechanisms of resistance to taxanes and therapeutic implications. Drug Resist. Updat. 2 (1999) 351-357
20. Geney R., Ungureanu M., Li D., and Ojima I. Overcoming multidrug resistance in taxane chemotherapy. Clin. Chem. Lab. Med. 40 (2002) 918-925
21. Deng L., Tatebe S., Lin-Lee Y.C., Ishikawa T., and Kuo M.T. MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer Treat. Res. 112 (2002) 49-66
22. Drukman S., and Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents. Int. J. Oncol. 21 (2002) 621-628 (Review)
23. Horwitz S.B., Lothstein L., Manfredi J.J., Mellado W., Parness J., Roy S.N., et al. Taxol: mechanisms of action and resistance. Ann. NY Acad. Sci. 466 (1986) 733-744
24. Verrills N.M., Po'uha S.T., Liu M.L., Liaw T.Y., Larsen M.R., Ivery M.T., et al. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J. Natl. Cancer Inst. 98 (2006) 1363-1374
25. Hari M., Loganzo F., Annable T., Tan X., Musto S., Morilla D.B., et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 5 (2006) 270-278
26. Wang Y., O'Brate A., Zhou W., and Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 4 (2005) 1847-1853
27. Kisurina-Evgen'eva O.P., Briantseva S.A., Stil A.A., and Onishchenko G.E. Antimicrotubule agents can activate different apoptotic pathways. Biofizika 51 (2006) 875-879